Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of this partnership, Foresee and TRPharm will collaborate to initially expedite the development of FP-045 in Fanconi Anemia. Turkey and the surrounding region has a high prevalence Fanconi Anemia as well as other rare diseases.
Lead Product(s): FP-045
Therapeutic Area: Rare Diseases and Disorders Product Name: FP-045
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Foresee Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 23, 2022